A two-part study was designed to determine whether the inclusion of the rodent liver 'S9' exogenous metabolic activating system contributes to the generation of misleading positive results by the regulator-required in vitro mammalian genotoxicity tests. The mono-oxygenase enzymes in S9 produce direct-acting DNA-reactive electrophiles, and are included in in vitro genotoxicity tests to enhance the detection of substances which only become genotoxic following metabolism. However, as the S9 system lacks 'detoxifying' phase 2 factors it was hypothesised that increased chemical metabolism per se may lead to an increase in irrelevant S9 test outcomes in safety assessment. To test this, 89 compounds with positive or negative carcinogenicity data were identified, which produced negative Ames test data (+/-S9), and only produced positive in vitro mammalian test data in the presence of S9. This allowed a determination of whether or not misleading predictions of carcinogenicity by the in vitro mammalian tests were more or less prevalent in the presence of S9. A subset of these compounds was then tested with and without S9 in the GADD45a-GFP genotoxicity test, in order to determine whether misleading in vitro mammalian positive results were generally more prevalent with S9, or reflected particular tests' liabilities. This study suggests that the use of S9 metabolic activation in in vitro genotoxicity tests does not increase the prevalence of misleading positive results in in vitro mammalian genotoxicity assays, at least amongst Ames negative compounds.
Introduction
The routine use of in vitro genotoxicity testing to identify potential human carcinogens began in the second half of the 20th century with the Salmonella typhimurium reverse mutation assay (the 'Ames' test: 1-3). The potentially confounding evolutionary gap between prokaryotic unicellular organisms and humans was bridged in the subsequent development of the in vitro mammalian cell, and animal (rodent) test models currently used in regulatory safety assessment for example ICH S2R (4) . A detailed description of these tests is beyond the scope of this article. It is important to recognise that the differences between prokaryotes and eukaryotes extend beyond differences in chromosome structure and mechanisms of chromosome segregation. Significantly the higher eukaryotes, including humans, are able to neutralise a wider variety of toxins, with liver playing a critical role in the metabolism of genotoxins into compounds that can be excreted via the kidneys. In simple terms this process can be divided into two phases: (i) oxidation by cytochrome P450 monooxygenase enzymes; (ii) conjugation of oxidation products to other molecules neutralising and targeting them for excretion (5) . In the safety assessment of novel chemicals, these reactions, and in particular, the generation of reactive oxidation products, are recapitulated by the inclusion of liver extracts into the in vitro genotoxicity test protocols. The most commonly used preparation of these enzymes, 'S9', has been incorporated into all of the in vitro genotoxicity test batteries (1, 4, 5) . The phase 1 cytochrome P450 mono-oxgenases are well-represented in these extracts, but the phase 2 conjugation systems less so (6) . As a consequence, the DNA reactive phase 1 products predominate, making the process very sensitive, but potentially liable to produce positive results for compounds that may otherwise be effectively neutralised in humans. In the overall genotoxicity safety assessment, further metabolic analysis or in vivo studies can be used to mitigate such concerns. However, following the adoption of Directive 2003/15/EC as the 7th amendment of the Cosmetics Directive, animal testing was no longer permitted for cosmetic products/ingredients for sale in the EC. There is therefore an increasing dependence on robust in vitro testing batteries and weight of evidence approaches to safety assessment: it is important to recognise both the strengths and the weaknesses of these various tests.
Kirkland et al. (7) reviewed in vitro and in vivo study data from over 700 compounds with carcinogenicity study data. They revealed that the likelihood of producing misleading ('false') positive predictions of carcinogenic hazard varied widely in the in vitro tests. The Ames test had a reasonable specificity (73.9%), but none of the regulatory in vitro mammalian tests produced specificity values above 45%: memorably the authors commented that 'a better prediction of carcinogenic potential might be obtained by flipping a coin'. This triggered a re-evaluation of test protocols and subsequently revised test guidance for pharmaceuticals (4) , including a reduction in the top testing dose from 10 to 1 mM. Amendments to protocols were subsequently adopted into the relevant Organisation for Economic Co-operation and Development (OECD) documents, with reduction in top testing dose to 10 mM or 2 mg/ml, whichever is the lower. The 'specificity issue' also stimulated interest in alternative, non-regulatory in vitro tests. Amongst these, a green fluorescent protein (GFP) reporter assay for the expression of the GADD45a gene in human, p53 wild-type Tk6 cells ('GreenScreen HC': abbr. GSHC) was notable for its high specificity, both without S9, 100% (8) and with S9 activation, 91.3% (9); 95% (10) . These studies were not as extensive as the Kirkland review, but the specificity values calculated for the in vitro mammalian tests within the GSHC validation collections were all lower than that of GSHC: chromosome aberration (CA)/micronucleus test (MNT) 63%; mouse lymphoma assay (MLA) 78%. The high specificity of the Ames test within GSHC validation exercises reflected the deliberate selection of Ames negative, non-carcinogens for the assessment of specificity.
Kirkland and coworkers did not discriminate between Ames and in vitro mammalian cell test data generated with S9 and without S9. The overall aim of this study was to fill that gap, and discover the extent to which the inclusion of S9 affects the accuracy of the regulatory battery. A review of published studies identified a collection of compounds in which data with and without S9 inclusion were discriminated. This was followed by the testing of a readily available subset of these compounds in the GSHC assay. The results therefore provide an insight into influence of S9 on the outcome of several different in vitro mammalian tests.
Materials and methods
Selection of compounds that require exogenous metabolic activation to produce positive results in in vitro mammalian genotoxicity tests Data were collected from the following sources: The Carcinogenic Potency database (CPDB) http://potency.berkeley.edu/; The National Toxicology Program (NTP) http://ntp-server.niehs.nih.gov/; Kirkland et al. (7) ; The Physicians' Desk Reference (61st Ed. Montvale, NJ: Thomson PDR, 2007). The list was compiled by a retrospective analysis of the data from all the compounds in Kirkland et al. (7) .
The initial search was for published studies that discriminated between positive results generated with and without S9 exogenous metabolism. To simplify the analysis, where separate positive and negative reported results were identified, either in the presence or absence of exogenous metabolism, they are recorded as positive; where a single report produced equivocal (positive and negative) results, it is recorded as equivocal. Table 1 presents data for Ames  negative rodent non-carcinogens; Table 2 presents data for Ames negative rodent carcinogens. No distinction was made between genotoxic and non-genotoxic mechanisms of action either in this selection, or in the original investigation by Kirkland et al. (7) . This is mainly due to the paucity of published mechanistic studies which would allow such distinction. The analysis focused on the in vitro mammalian assays, since it is these which have been demonstrated to be most prone to the generation of misleading positive results (poor specificity). Ames positive compounds were excluded from this analysis because it has a high specificity c.f. in vitro mammalian assays: Kirkland et al. (7) and because it is routinely performed in the presence and absence of S9: it identifies DNA reactive compounds. In many sectors, a positive result in the Ames test can be sufficient to terminate compound development.
Published studies for compounds with data from all the regulatory in vitro tests (i.e. from the Ames test, an in vitro mutation assay-MLA or HPRT-and an in vitro CA assay) were very limited: indeed, many reference sources only had data from a single in vitro regulatory assay. The data review was further limited by the availability of detailed experimental data: many sources simply list test results without providing experimental conditions, or the method of cytotoxicity estimation or the maximum test concentration. For this reason, compounds were only included in this study if the reference cited by Kirkland et al. (7) actually provided the experimental details to allow a decision to be made on whether the inclusion of S9 was required for a positive result to be determined. This approach inevitably limited the number of compounds identified which require S9 to produce positive results.
GreenScreen HC studies
The GSHC data from tests with and without S9 were performed according to published protocols (8) (9) (10) . Briefly, a 96-well microplate was used to test four compounds each at nine, 2-fold dilutions with both the GFP reporter and control strain (non-GFP producing, out-of-frame mutation). In tests without S9, test compounds were incubated for 48 h and data were collected spectrophotometrically. In studies with S9, test compounds were incubated for 3 h in the presence of S9 from Aroclor 1254-treated rats (1% in 0.15M KCl: Moltox inc., Boone, NC, USA), harvested and washed then incubated for a further 45 h. Data were then collected using flow cytometry. Since the intention was that the results of this study should be relevant in all chemical sectors, all compounds were tested to a top dose of 10 mM unless limited by solubility or toxicity. The cytotoxicity and genotoxicity test outcomes were determined from independent triplicate tests. A positive result for cytotoxicity is defined as a reduction in relative cell density (RCD) to below 80% in the absence of S9, and a reduction in relative population survival (RPS) below 90% in the presence of S9. The different values reflect the different methods for toxicity assessment between the two assays: without S9, light absorbance is used to determine the extent of cell proliferation; in the S9 assay, cell viabilities, estimated using propidium iodide and flow cytometry, are used. A positive result for genotoxicity is recorded when GFP output (normalised to cell density without S9, and to cell number with S9) increases more than three times the standard deviation in the constitutive signal derived from non genotoxins in validation studies (8) . For studies without S9, this figure is 1.5-fold, for studies with S9 it is 1.3-fold. These threshold numbers were also derived from published validation studies (8, 9) . Again the different values reflect the use of different data collection methods.
Results
The inclusion of S9 in in vitro mammalian tests increases the prevalence of positive results amongst Ames negative non-carcinogens
The literature review identified 196 compounds for study, comprising 67 Ames negative rodent non-carcinogens and 129 Ames negative rodent carcinogens. All had positive genotoxicity data from a least one of the in vitro mammalian assays (MLA, MNT, CA).
Thirty-seven of the 67 rodent non-carcinogens produced positive in vitro data only in the absence of S9 and were not considered further. The remaining 30 non-carcinogens produced positive or equivocal data in the presence of S9. Seventeen of these 30 produced positive genotoxicity data in at least one in vitro genotoxicity study, only in the presence of S9; 13 of the 30 produced positive results both with and without S9 ( Table 1 ). Very few of the 30 noncarcinogens reviewed had data from all three in vitro tests, with and without S9 and in similar testing conditions. Indeed, none of the non-carcinogens reviewed produced positive results with S9 alone in all three in vitro mammalian genotoxicity assays. For this reason, the analysis below considers each of the in vitro mammalian tests separately. MLA produced positive data for seven compounds in the presence of S9 only, and one compound in both the presence and absence of S9. The MNT produced positive data for two compounds in both the presence and absence of S9 (none were only positive with S9). Chromosome aberration studies produced positive data for seven compounds in the presence of S9 only and two compounds in both the presence and absence of S9.
There were 11 compounds positive in two of the three tests, in the presence or absence of S9. Three of the 11 Ames negative (non-carcinogens) only produced misleading and unique positive results in the presence of S9, and in more than one assay: O-anthranilic acid (positive in MLA and MNT); C.I. acid orange 10 (positive in CA, equivocal in MLA); 1-phenyl-2-thiourea (positive in MLA and CA). The eight remaining Ames-negative non-carcinogens produced positive results in one or more assays in both the presence and absence of exogenous metabolism in the same test or a different test (see Table 1 ), and are hence not classified as pro-mutagens. Chlorpropham and penicillin VK both produced positive results in the MLA in the presence of S9 only, though in other studies both produced positive results for CA in the absence of S9. Three compounds, eugenol, lithocholic acid and resorcinol, only produced positive results in CA in the presence of S9, but generated positive responses in the MLA in both the presence and absence of S9. Only eugenol produced a clear positive response both with and without S9 in the MLA: lithocholic acid and resorcinol produced equivocal results in the MLA. Phenol produced positive results No rodent carcinogens in this study were identified that required S9 to produce positive results in all three assays. However, the overlap between the cytogenetic endpoints assessed by CA and MN induction suggests that the limited number of positive results in the MNT is due to a lack of published studies rather than a lower sensitivity in this assay in the presence of S9.
The remaining 21 of these 59 carcinogens all generated positive results in both the presence and absence of S9. Ten compounds were positive only in MLA; five compounds were positive only in the CA test; one compound (1,1,2-trichloroethane) was only positive in MNT. The remaining five compounds required S9 for a positive result in one test, but produced positive results without S9 in a second test [benzene, ciprofibrate, 1,4-dichlorobenzene, phenazopyridine HCl, and trichloroethylene (TCE)].
Summary of in vitro genotoxicity results from Ames negative compounds with carcinogenicity data
One hundred and ninety six compounds were reviewed in this study: 67 non-carcinogens and 129 rodent carcinogens. Amongst the 67 non-carcinogens, 30 compounds (44.7%) were identified where positive results were produced by at least one of the regulatory in vitro mammalian tests in the presence of S9. However whilst 17 of these 30 produced positive results only in the presence of S9, the remaining 13 produced positive results both with and without S9. Hence overall there were 17/67 compounds (25.4%) that were misclassified as potential carcinogens on the basis of an S9 study.
Amongst the 129 carcinogens, 59 compounds (45.7%) were identified where positive results were produced by at least one of the regulatory in vitro mammalian tests in the presence of S9. Thirtyeight of these 59 (64.4%) produced positive results only in the presence of S9. The remaining 21 produced positive results in both the presence and absence of S9. Hence overall only 38 of the 129 (29.5%) carcinogens required S9 for their detection.
In considering these results it is important to recognise that for those developing novel compounds, there is initially no carcinogenicity data: follow-up studies are required to resolve the typical data conflicts (Ames negative, in vitro mammalian cell positives). With this data collection, there is a benefit of carcinogenicity study data, and this allowed a further analysis to determine whether the misleading results were due to S9 itself (with its lack of phase II metabolism) or the poor specificity of the regulator-required test systems revealed by the Kirkland studies. A subset of readily available compounds with data conflicts was subjected to an additional mammalian cell test: the GADD45a-GFP GSHC assay (+/-S9). It was chosen because published validation studies have demonstrated a much higher specificity than the regulator-required tests. If the addition of S9 is a generally confounding factor for the in vitro tests, then GSHC should also produce a lower specificity in the presence of S9.
GSHC assay data (+/-S9) for 28 Ames negative noncarcinogens and 23 Ames negative carcinogens, which have positive regulatory in vitro data
GSHC assay data were produced for a readily available subset of 51 compounds from the study above. The subset comprised 28 Ames negative, in vitro positive non-carcinogens and 23 Ames negative, in vitro positive carcinogens. All were tested in the absence and presence of S9. A summary of the GSHC results produced from the noncarcinogens is provided in Table 3 (without and with S9) and for carcinogens in Table 4 (without and with S9). Data were produced for both cytotoxicity and genotoxicity assessments as the outcome of independent triplicate tests and presented as positive (+), negative (-), un-interpretable ('U') or equivocal (E). Example GSHC genotoxicity and cytotoxicity data from four non-carcinogens tested in triplicate in the GSHC assay are shown in Supplementary Figure 1 
GADD45a-GFP results for 28 Ames negative non-carcinogens tested in the absence of S9
Twenty-five of the 28 non-carcinogens produced clear negative results in the absence of S9 (Table 3) . One compound, C.I. acid orange 10, produced uninterpretable genotoxicity data due to its high autofluorescence, which interfered with the collection of GFP data. Two further compounds, 1-phenyl-2-thiourea and resorcinol, produced equivocal results for genotoxicity. With the 2 equivocals counted positive, 25 of the 27 (93%) non-carcinogens with interpretable data produced clear negative genotoxicity results: if counted as negative the figure rises to 100%. This is consistent with the high specificity values derived in earlier validation studies. At the highest tested doses, 17 compounds showed cytotoxic effects (reduction in RCD below 80%) within the data acceptability range (RCD ≥ 30%). 8 were not cytotoxic at any dose in the testing range.
GADD45a-GFP results for 28 Ames negative non-carcinogens tested in the presence of S9
Twenty-five of the 28 non-carcinogens (89.2%) produced clear negative results in the presence of S9 (Table 3) . Two of the three remaining compounds produced positive results for both genotoxicity and cytotoxicity: malathion and 1-phenyl-2-thiourea. The third, resorcinol, was cytotoxic (within the data acceptability criteria) and produced both positive and negative results for genotoxicity in the assay in separate experiments: it was therefore classified as equivocal (E+S9). At the highest tested doses, 18 compounds showed cytotoxic effects within data acceptability criteria. Ten were not cytotoxic at any dose in the testing range.
Summary of GADD45a-GFP data from 28 Ames negative non-carcinogens in the absence and presence of S9
The GSHC assay was included in this study because its reported specificity is higher than that of the regulator-required in vitro mammalian cell assays, and it offered the opportunity to discover whether this advantage was reduced by the inclusion of S9. It is clear that this assay is effective in the identification of non-carcinogens that produce conflicts between Ames and MN/CA data in the absence or presence of S9. This study demonstrated that S9 is not a confounding factor for the GSHC assay.
GADD45a-GFP data from 23 Ames negative carcinogens in the absence and presence of S9
To be consistent with our approach, 23 readily available Ames negative rodent carcinogens from the analysis above were also tested in the GSHC assay in the presence and absence of S9 (Table 4 ). The cytotoxicity and genotoxicity test outcomes from independent triplicate tests are summarised in Table 4 below. Example GSHC genotoxicity and cytotoxicity data from four Ames negative carcinogens are shown in Supplementary  Figure 3 
GADD45a-GFP results for 23 Ames negative carcinogens tested in the absence of S9
Of the 23 Ames negative rodent carcinogens assessed for genotoxicity in GSHC in the absence of S9, 14 compounds reduced RCD to below 80% (and within the acceptable toxicity range) indicating a cytotoxic effect. Just one of these compounds, phenolphthalein, produced a positive response for genotoxicity in the absence of S9. Two further compounds, C.I. direct blue 15 and C.I. direct blue 6, produced un-interpretable results due to their intense coloration that interfered with the assessment of cytotoxicity and genotoxicity in the absence of S9. The remaining seven rodent carcinogens all produced negative results for both cytotoxicity and genotoxicity in the assay.
GADD45a-GFP results for 23 Ames negative carcinogens tested in the presence of S9
Six of the 23 Ames negative rodent carcinogens assessed for genotoxicity in the GADD45a-GFP assay in the presence of S9 produced positive results. These include phenolphthalein, which also produced positive results for both cytotoxicity and genotoxicity in the absence of S9, and C.I. direct blue 6 (again classified as un-interpretable due to the coloration). Sixteen of the 23 produced clear negative results (69.6%) and none of these reduced percentage survival below the positive cytotoxicity threshold of 90%. Supplementary Figure 4 shows example data from the mean results of 4 compounds tested in triplicate: cinnamyl anthranilate (panel A); heptachlor (B); safrole (C) and styrene (D). Cinnamyl anthranilate, heptachlor and safrole all reduced percentage survival to below the threshold for cytotoxicity (within data acceptability criteria), and induced the GADD45a-GFP reporter above the 1.3-fold positive genotoxicity threshold. Styrene did not reduce percentage survival below levels seen in the untreated control at any of the concentrations tested and did not induce the GFP reporter.
Summary of GADD45a-GFP data from 23 Ames negative carcinogens in the absence and presence of S9
Carcinogens may act through genotoxic or non-genotoxic (including epigenetic) mechanisms of action, and the selection of Ames negative rodent carcinogens was expected to bias the collection towards non-mutagenic mechanisms and compounds activated by mammalian enzymes other than cytochrome P450s. The 'formal' sensitivity of the Ames test in this selection is 0%, suggesting that the majority of these carcinogens might have a non-mutagenic mode of action. It was therefore anticipated that GSHC would also produce a low sensitivity figure, due its high specificity to genotoxic carcinogens, and this was indeed the case.
Discussion
This study was designed to assess the impact of S9 on the specificity of the regulator-required in vitro mammalian cell genotoxicity tests. An extensive literature review identified a test set of Ames negative non-carcinogens with accompanying in vitro genotoxicity data. This approach inevitably excluded compounds for which S9 produced misleading Ames positives, but pragmatically this reflects the fact that it is rare for Ames positive compounds to be carried forward into development. For balance, a collection of Ames negative carcinogens was also identified, though this does produce some artefacts: zero sensitivity for the Ames test and a low figure for GSHC. Moreover, this study did not distinguish between genotoxic and non-genotoxic modes of carcinogenesis as there is a general lack of definitive mechanistic carcinogenicity data available to allow this distinction. Data were also collected from the pan-mechanistic GSHC genotoxicity assay in order to discover whether or not S9 was a generally confounding factor for in vitro genotoxicity tests. Fifty-nine (45.7%) of the 129 Ames negative rodent carcinogens investigated produced positive results in at least one in vitro assay which included S9. Whilst this might suggest that around half of eukaryote-specific genotoxic compounds are pro-genotoxins (and hence that S9 is important to the sensitivity of in vitro genotoxicity assays), only 38 of the 129 (29.5%) actually required S9 to produce a positive result i.e. ~70% of carcinogens produce positive results without S9 in at least one test.
Thirty (44.8%) of the 67 Ames negative rodent non-carcinogens produced positive results in at least 1 in vitro assay that included S9. However, only 17 (25.4%) actually required S9 to produce a positive result. The remaining 50 (74.6%) of the Ames negative noncarcinogens produced misleading positive results without S9 in one or other of the in vitro mammalian tests (100% minus the 25.4% misclassified by S9). As a consequence it is clear that S9 in itself is not the major contributor to the generation of misleading in vitro positive results, at least amongst Ames negative test compounds: it is the lack of specificity in the regulator-required tests themselves. This supports the findings of the Kirkland review (7) that the regulatory in vitro assays have poor specificity.
The majority of compounds producing misleading positive regulator-required in vitro genotoxicity assays for non-carcinogens, regardless of the presence or absence of S9, produced negative results in the GSHC assay-irrespective of S9 conditions. The majority of the compounds producing negative data were tested at concentrations where clear cytotoxicity (within data acceptability criteria) was observed. This confirms the higher specificity of this test, established in validation studies (8) (9) (10) , and demonstrates that S9 is also not a confounding factor for the GSHC assay. The apparently reduced sensitivity of the GSHC assay within this compound set (c.f. validation studies) is perhaps a consequence of the limitations imposed by a study focused on specificity. The selection of Ames negative carcinogens (with and without S9) inevitably biased the collection towards carcinogens with a non-genotoxic mode of action. Indeed there is evidence in the literature to support the conclusion of a non-genotoxic mechanism of carcinogenicity for six compounds in this study-all of which produced the expected negative GSHC result. A further four compounds were genotoxic carcinogens, and the remaining three had conflicting conclusions. For completeness all of these are discussed below. Aniline HCl produces tumours in rats but not mice (CPDB). Bomhard and Herbold (34) concluded that the animal studies were carried out at irrelevant high doses, with no relationship between the damage to chromosomes and induction of splenic tumours. 1,2,3,4,5,6-Hexachlorocyclohexane produced tumours in both rats and mice, but the initiating event is high dose-induced hyperplasia rather than genotoxic damage (35) (36) (37) and tumour progression was reversed following withdrawal of treatment (38) . Methylphenidate HCl data were reviewed by Teo et al. (39) and concluded that the weight-of-evidence from these studies did not suggest carcinogenic risk to humans in general, and specifically, that there was a lack of risk based on a genotoxic mechanism: NTP characterised methylphenidate as non-genotoxic. Trichloracetic acid was discussed by Corton (40) , who concluded that the predominant mechanism for tumour induction was through non-genotoxic activation of peroxisome proliferator activated receptor alpha in mice. The data on TCE were reviewed by Clay (41), who concluded from published studies that renal tumours produced in rodents are non-genotoxic in origin. The data for 4-vinylcyclohexene were considered by the Health Council of the Netherlands (42) . Whilst it is considered as carcinogenic to humans, the genotoxicity data is not convincing: the in vivo data is not dose-related; it is Ames negative, and the NTP MLA data were classified uninterpretable.
There were four genotoxic carcinogens that were not identified by the standard GSHC assay (+/-S9). Chlorobenzilate, is a mouse liver carcinogen, but produces no tumours in rats (43) . It is negative in the Ames test except when incubated with rat glutathione transferase GSTT-1. Styrene requires conversion to styrene-7,8-oxide to produce DNA adducts and rodent tumours (44, 45) . This metabolic activation step does not occur sufficiently in standard genotoxicity assays in the presence of S9 (45) . Styrene-7,8-oxide was reported positive in GSHC without S9 in a previously reported study (46) . Vinylidene chloride only produced positive results in in vitro studies where glutathione-S-transferase levels were elevated (47) . There is also some dispute about the reliability of rodent carcinogenicity data (48) . Benzene is a known human carcinogen, with activity associated with its oxidation products (49) for risk assessment, but its volatility makes the GSHC assessment unreliable.
Three additional compounds produced conflicting data, but the distinction between genotoxic and non-genotoxic MOA was less easily made. For acrylamide, Bolger et al. (50) concluded that there was insufficient evidence to support a non-genotoxic mechanism, though others (51) concluded that a non-genotoxic MOA was supported because tumours were formed in animals at doses where no genotoxic damage was detected. Bromodichloromethane data has also been reviewed by several authors: the NTP report on carcinogens found no evidence of carcinogenic activity (52) , whilst the Health Council of The Netherlands concluded that there was sufficient evidence for it to be considered as carcinogenic to humans, with a stochastic genotoxic mechanism (53) . Pyrilamine maleate is a widely used antihistamine. It produces liver tumours in male and female rats, but not tumours in mice (54) .
Conclusion
It is clear from this analysis that when an Ames negative compound produces a positive result with S9 in a single regulatory in vitro mammalian test, this should not lead to the expectation of a positive result in a second in vitro mammalian test in the presence of S9. Positive results were often observed for a compound, tested with S9 only in one assay, and without S9 in a different study in the same assay, or in a different assay. This observation applies to both correctly predictive in vitro positive results from Ames negative rodent carcinogens, and to misleadingly predictive in vitro positive results for Ames negative non-carcinogens. The prevalence of misleading positive results in in vitro genotoxicity tests is therefore largely independent of the inclusion of S9 in the assay, at least amongst Ames negative compounds, and affects both mutagenic and cytogenetic endpoints.
